CancerAppy is a biotech specialized in the field of cancer research, focused on the discovery and development of new therapeutic targets, based on its own artificial intelligence methodology
We have developed solutions that allow us to be more efficient and precise in the discovery of small molecules.
We work in the early stage of the Drug Discovery Value Chain.
From the initial analysis of the Target to the preclinical phase
Target ID & Validation
Using artificial intelligence algorithms, we work on identifying new potential oncological targets.
Hit discovery
We found potential hits from extensive libraries containing up to 1B of compounds in a fast way.
Hit-to-Lead
We sieve the results obtained based exclusively on scientific criteria to eliminate negative results and reduce the number of false positives.
Lead Optimization
We optimize the structure of the selected lead to improve its on-target activity while reducing its off-target interactions.
Preclinical Development
Each of the potential leads found in silico is tested in vitro internally, to validate the computational results.
Thanks to our deep knowledge and expertise in oncology and AI, we use a massive amount of multimodal data in our state-of-the-art AI algorithms, helping to identify new therapeutic targets, identify lead compounds, and determine the mechanism of action of a given compound. as well as possible drug combinations.
Contact us
We would be happy to talk to you.
News
Latest news about CancerAppy…
Venture on the Road
Part of our team was enjoying "Venture on the Road" at innolab Bilbao.
4YFN
Cancerappy has been selected to participate in the Espacio España 4YFN 2020. 4YFN is an event of MWC Barcelona, with a combined attendance of...
Programa “Emprende” RTVE
TV show 'Emprende' (RTVE) has echoed the Speedway Training initiative promoted by Banco Caminos and Bancofar in which cancerappy is selected. From...
Grant CPP2021-008597 funded by:
Grant TQ2020-011486 funded by:
Subvencionado por el CDTI
Somos cliente Enisa
